The review, published in the Current Neuroscience Journal by Priyanka Yadav, Dinesh Kumar, Anil Kumar, and corresponding author Sumit Kumar, maps the molecular chain of events through which oxidative stress drives the destruction of nerve cells. Drawing together evidence across five major neurological conditions — Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and epilepsy — the authors make a case that is both sobering and constructive: oxidative stress is not a single entity that can be neutralised with a single pill, but a family of disease-specific chemical processes that demand precision-targeted interventions.

At modest levels, reactive oxygen species are not merely harmless; they are essential. They participate in nerve cell signalling, help sculpt the synaptic connections that underlie learning and memory, and support immune responses within brain tissue. The trouble begins when production outpaces the brain’s capacity for neutralisation, a state scientists call oxidative stress. Because neurons are rich in the polyunsaturated fatty acids that reactive molecules attack most readily, and because the brain maintains comparatively weak antioxidant defences relative to other organs, it is uniquely vulnerable to this kind of chemical damage. Once stress becomes sustained, the consequences cascade: fatty cell membranes are peroxidised, proteins are corrupted and lose their function, DNA strands accumulate lesions, mitochondrial energy machinery falters, chronic inflammation takes hold in brain tissue, and misfolded proteins begin to aggregate into the abnormal clumps that define several neurodegenerative diseases.

What makes the review particularly valuable is its insistence on mechanistic specificity. All five diseases share a common foundation — failing mitochondria, weakened antioxidant defences, excitotoxic excess at synapses, chronic low-grade neuroinflammation, and the accumulation of proteins the cell cannot clear. But the specific chemical routes by which oxidative stress inflicts damage diverge dramatically, and those differences have profound implications for therapy.

Consider Parkinson’s disease, a condition defined by the death of dopamine-producing neurons. Dopamine itself is a chemically restless molecule. Its normal metabolic breakdown generates reactive quinones — dopamine quinones — that are directly toxic to the very neurons that manufacture the neurotransmitter. The result is a self-reinforcing cycle of destruction: the more dopamine is metabolised, the more toxic byproducts accumulate, and the fewer healthy neurons remain to handle the load. Any antioxidant strategy for Parkinson’s that ignores this dopamine-specific chemistry is, the authors suggest, unlikely to succeed.

In amyotrophic lateral sclerosis, the story unfolds differently. Mutations in the SOD1 gene, which encodes one of the cell’s most important antioxidant enzymes, produce a misfolded protein that is not merely inactive but actively poisonous. This corrupted enzyme disrupts redox balance with particular specificity in motor neurons — the large, metabolically demanding cells that control voluntary movement — helping explain why ALS devastates movement while leaving cognition and sensation comparatively intact for much of the disease course.

Alzheimer’s disease presents yet another mechanism. The amyloid-beta fragments that accumulate into the disease’s characteristic plaques act as catalysts for redox-active metal ions such as copper and iron. In the presence of these metals, amyloid-beta drives the generation of highly reactive hydroxyl radicals, producing sharply localised oxidative damage in the immediate vicinity of plaques. Oxidative stress in Alzheimer’s is thus not a diffuse background phenomenon but a concentrated chemical assault, orchestrated in part by the very protein aggregates considered hallmarks of the disease.

Huntington’s disease adds a fourth variant. The mutant huntingtin protein physically impairs mitochondrial function, choking off energy supply and simultaneously increasing the generation of oxidative byproducts. This double blow falls hardest on the striatum, the brain region most affected by the disease, providing a mechanistic explanation for the movement disorders and cognitive decline that characterise the condition. Epilepsy, meanwhile, illustrates how oxidative stress and excitotoxicity feed each other: excessive neuronal firing generates reactive species, which in turn damage the cellular machinery that normally restrains excitability.

The review also devotes careful attention to how oxidative damage is actually measured, an issue of more than academic interest. Researchers rely on a panel of biomarkers: F2-isoprostanes and malondialdehyde as indicators of lipid peroxidation, protein carbonyls and 3-nitrotyrosine as markers of protein oxidation, and 8-hydroxy-2′-deoxyguanosine as evidence of DNA damage. Crucially, the authors draw a conceptual distinction between oxidative stress — the imbalance between production and defence — and oxidative damage, the measurable molecular harm that results. A cell can be under significant stress without yet showing damage if its defences are compensating, and a treatment that reduces one without addressing the other may produce encouraging biomarker readings while failing to change the disease’s trajectory.

This distinction feeds directly into the review’s most provocative argument: an explanation for why antioxidant therapies have so consistently disappointed in clinical trials. Despite decades of compelling laboratory evidence linking oxidative stress to neurodegeneration, broad-spectrum antioxidants have repeatedly failed to deliver meaningful benefits to patients. The authors identify several reasons. Antioxidant drugs must cross the blood-brain barrier in sufficient concentrations, a formidable pharmacological obstacle. Many act at the wrong point in the damage cascade or against the wrong reactive species. Preclinical disease models frequently fail to capture the complexity and chronicity of human neurodegeneration, producing results that simply do not translate.

But the deepest problem may be conceptual. Reactive oxygen species are not waste products to be eliminated; they are signalling molecules woven into the normal fabric of brain function. Indiscriminately suppressing their production risks disrupting the very cellular processes a therapy is meant to protect. A blunt chemical hammer, in other words, cannot fix a system that depends on precisely calibrated chemistry.

The path forward, the authors argue, requires abandoning the shotgun approach. Future therapies should target the specific oxidative pathways relevant to each disease — dopamine quinones in Parkinson’s, SOD1 misfolding in ALS, metal-catalysed oxidation in Alzheimer’s, mitochondrial impairment in Huntington’s — and must be deployed at the appropriate stage of disease progression and within the appropriate cellular compartment. Timing matters as much as target: intervening after decades of accumulated damage may be futile even with the right molecule. Equally important is the smarter use of oxidative damage biomarkers in clinical trials, both to identify the patients most likely to benefit from antioxidant interventions and to verify that a treatment is genuinely reducing oxidative stress in the brain rather than merely performing well on surrogate measures.

For the tens of millions of people worldwide living with these five conditions, and for whom disease-modifying treatments remain painfully elusive, the review offers neither a cure nor a quick breakthrough. What it offers instead is something arguably more valuable at this stage: a coherent mechanistic framework that explains past failures and charts a disciplined route toward therapies that treat oxidative stress not as a generic enemy to be eradicated, but as a set of distinct, disease-specific vulnerabilities to be precisely addressed. In the difficult terrain of neurodegeneration, that kind of clarity may prove to be the most powerful medicine of all.

Parkinson’s disease, a progressive neurodegenerative disorder characterized primarily by motor dysfunction due to dopaminergic neuron loss, has been notoriously difficult to dissect at a molecular level. While mitochondrial dysfunction has long been implicated as a cardinal feature of PD, the intricate pathways through which mitochondrial perturbations potentiate neurodegeneration remained elusive. This study by Zhang et al. bridges this gap by elucidating how mitochondrial defects precipitate metabolic shifts within the TCA cycle, consequentially impacting epigenetic enzymes that dictate chromatin states and gene expression profiles relevant to neuronal survival.

The TCA cycle, central to cellular energy production, operates within the mitochondria to generate reducing equivalents that fuel oxidative phosphorylation. The researchers demonstrated that mitochondrial impairment leads to a marked remodeling of TCA cycle metabolites, causing an accumulation or depletion of critical intermediates. These metabolic changes were shown to have a direct impact on the activity of histone demethylases, particularly those responsible for removing trimethyl marks on lysine 4 of histone H3 (H3K4me3). The inhibition of these demethylases disrupts gene expression programs essential for neuronal health, thereby linking metabolic anomalies to epigenetic dysregulation.

At the heart of this mechanistic insight is the finding that mitochondrial dysfunction reduces α-ketoglutarate (α-KG) availability, a key cofactor for the family of Jumonji C (JmjC) domain-containing histone demethylases. These enzymes catalyze the demethylation of H3K4me3 marks, a histone modification associated with active transcription. When α-KG levels drop due to impaired TCA cycle function, demethylase activity plummets, resulting in aberrant retention of H3K4me3 marks. This hypermethylated chromatin state leads to persistent activation or repression of gene sets that eventually culminate in neuronal demise.

Further experimental validation using cellular and animal models underscored the causative nature of this mitochondrial-metabolic-epigenetic axis. By experimentally inducing mitochondrial dysfunction, the authors recapitulated the TCA cycle remodeling and subsequent H3K4me3 accumulation, reinforcing the causal chain. Remarkably, restoring α-KG levels or chemically modulating histone demethylase activity partially rescued neural phenotypes, suggesting that targeting metabolic-epigenetic crosstalk could represent a transformative therapeutic strategy.

Beyond identifying the molecular players involved, the study also employed comprehensive transcriptomic analyses to map the downstream gene expression changes driven by altered histone methylation. Genes pivotal for neuronal survival, mitochondrial biogenesis, and oxidative stress responses were among those dysregulated, revealing how epigenetic modifications transmit metabolic stress signals into changes in cellular function and ultimately neurodegeneration.

This integrated approach combining metabolomics, epigenomics, and neurobiology underscores the importance of systems-level understanding in neurodegenerative disease research. The discovery that metabolic intermediates serve as epigenetic cofactors underscores an emerging paradigm wherein metabolism dynamically regulates gene expression and cell fate decisions. In PD, this metabolic-epigenetic coupling emerges as a key vulnerability that could be exploited therapeutically.

The implications of this research extend beyond Parkinson’s disease. By highlighting the critical role of mitochondrial metabolic state in regulating epigenetic landscapes, these findings suggest a broader relevance to other neurodegenerative conditions marked by mitochondrial decline and chromatin dysfunction, such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). This cross-disease perspective may catalyze the development of broad-spectrum neuroprotective strategies targeting metabolic and epigenetic interactions.

One of the most exciting prospects arising from this work is the potential to repurpose metabolic cofactors or develop small molecules to restore histone demethylase activity in PD. Given that metabolic remodeling is a reversible process, therapeutic interventions designed to rebalance TCA cycle function or supplement deficient metabolites like α-KG could reverse detrimental epigenetic marks and reinstate healthy gene expression programs. This metabolic epigenetics approach opens a new frontier distinct from conventional dopamine replacement therapies, which do not address underlying neurodegeneration.

Moreover, the study brings attention to the need for precision medicine in neurodegenerative diseases. Since mitochondrial dysfunction varies among PD patients, metabolic profiling might help stratify patients who would benefit most from epigenetic-based therapies. Combined with advanced biomarker development and targeted delivery methods, such approaches hold promise to significantly improve clinical outcomes and quality of life for those suffering from PD.

In conclusion, Zhang and colleagues have provided a paradigm-shifting insight into Parkinson’s disease, spotlighting the interplay between mitochondrial dysfunction, metabolic remodeling of the TCA cycle, and epigenetic inhibition of H3K4me3 demethylation as a driving force of neurodegeneration. This discovery not only enriches our mechanistic understanding but also suggests innovative therapeutic avenues by targeting metabolic cofactors and epigenetic enzymes. As the neurodegenerative field embraces this metabolic-epigenetic nexus, future research will likely unravel further complexities and pave the way for novel, effective treatments against PD and related disorders.

The compelling evidence that altering mitochondrial metabolism influences chromatin states to promote neurodegeneration validates a holistic approach in neuroscience research, where metabolism, epigenetics, and neurobiology are interwoven rather than studied in isolation. Such integrated frameworks are essential to unveil the multifactorial nature of diseases like Parkinson’s and ultimately enable breakthroughs that can transform patient care.

Looking ahead, clinical translation of these findings will require rigorous testing of metabolic and epigenetic modulators in preclinical models and eventually human trials. Equally important is the identification of reliable biomarkers for mitochondrial and epigenetic dysfunction, which would aid early diagnosis and therapy monitoring. With continued multidisciplinary collaboration, the hope is that metabolic-epigenetic therapies will evolve from experimental insights into tangible clinical realities that halt or even reverse neurodegeneration.

As the scientific community digests these findings, the potential for harnessing mitochondrial metabolism to influence the epigenome represents a revolution in understanding cellular aging and neurodegenerative disease progression. This groundbreaking study lays a foundational stone toward integrating metabolism and chromatin biology in the fight against Parkinson’s disease, promising renewed hope and innovative strategies for millions affected worldwide.

Subject of Research: Mitochondrial dysfunction and metabolic remodeling of the TCA cycle in Parkinson’s disease; epigenetic regulation via inhibition of H3K4me3 demethylation.

Article Title: Mitochondrial dysfunction-mediated metabolic remodeling of TCA cycle promotes Parkinson’s disease through inhibition of H3K4me3 demethylation.

Article References:
Zhang, X., Zhang, F., Zeng, Y. et al. Mitochondrial dysfunction-mediated metabolic remodeling of TCA cycle promotes Parkinson’s disease through inhibition of H3K4me3 demethylation. Cell Death Discov. 11, 351 (2025). https://doi.org/10.1038/s41420-025-02651-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02651-1